Plain-English translation of NCT05838521 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called in people with cervical cancer that has come back or continued to grow after prior chemotherapy. The medication works by attaching to cancer cells and delivering a toxic payload directly to them. Researchers want to learn how well this treatment works and whether it's safe for patients in this situation.
Cervical cancer that returns after initial treatment is very difficult to manage, and patients don't have many effective options. This trial exists to see if this medication—which uses a unique antibody-based approach—can help people whose cancer has progressed despite previous chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication over a 21-day cycle, with dosing in the first two weeks of each cycle. You would continue receiving this treatment until your cancer stops responding, unacceptable side effects occur, or you choose to stop. Throughout the trial, you'll have regular blood tests and imaging scans to monitor how well the medication is working and check for side effects.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States